Lost in PICO?

A simulation of the EU HTA scoping process

Autoren: Buchholz ISL, Stieglitz F, Hantke I, Schönermark MP

ISPOR Europe 2023 Posterpräsentation

Die Publikation ist ausschließlich auf Englisch verfügbar.

ISPOR Europe 2023

Das Abstract "Lost in PICO? A simulation of the EU HTA scoping process" wurde als Top 5% Finalist für die ISPOR Research Presentation Awards ausgewählt. Das Poster wurde im Rahmen der EU Joint Clinical Assessment Postertour als eines von sechs Postern auf der ISPOR vorgestellt. Die Postertour fand am 14. November von 11:30 Uhr - 12:15 Uhr statt.


The joint clinical assessment (JCA) according to Regulation (EU) 2021/2282 (EU HTA) will initially be implemented for oncology drugs and ATMPs from January 2025. All JCA procedures are commenced by the scoping process: The formulation of a member state-specific research question, represented as individual PICO schemes. Patient population, intervention, comparator, and study endpoints to measure the outcome are determined by the authorities as basis for clinical evaluation. Given the diversity of standards of care in Europe, multiple PICOs can be demanded. By simulating an EU HTA-like scoping process as of today, this analysis aims to assess the risk of receiving numerous PICOs. How complex will it be?


To determine heterogeneity of expected PICO schemes, completed national HTA assessments from the "EU big 6" member states were compared regarding several oncology drugs of specific indications. Procedures from the voluntary earlier joint clinical evaluation Joint Action 3 were used as supplement.


Complexity of the number and design of PICO schemes for oncologics was identified: chosen patient groups and interventions were largely consistent between HTA assessments, whereas selection of comparators differed and resulted in indication-dependent heterogeneity with up to 5 PICOs for 6 member states. The acceptance of outcomes was consistent, albeit relevance of progression-free survival varied significantly.


EU HTA is supposed to reduce redundancies and bureaucracy by harmonization. However, the diverse standard of care across member states needs to be reflected in the EU HTA dossier through numerous PICO schemes, especially in dynamic indications. This analysis supports the anticipation of strategic and operational effort for future EU HTA dossiers. Compared to national HTA procedures, this will create complexity and uncertainty in predictability of the statistical analyses required for assessment. It is therefore questionable whether EU HTA can comply with its objective.

- - -

Bildquelle: Neuroflash

Kontaktieren Sie uns

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 – 18


Hier stellen wir Ihnen unsere englisches Poster als kostenlosen Download zur Verfügung.

Lost in PICO? - A simulation of the EU HTA scoping process

EU-HTA: Europäische Nutzenbewertung (JCA)

Erlangen Sie mit uns Planungssicherheit: Richten Sie ihre Projekte und ihre Ressourcenplanung mit uns frühzeitig und umfassend auf EU-HTA und dessen Implikationen für den Market Access aus.

Market Access Strategie

Entwickeln Sie frühzeitig mit uns eine fundierte Market Access Strategie, welche Ihnen und allen Beteiligten eine wertvolle Orientierung während des gesamten Marktzugangs gibt.
nach oben